The European Commission has approved a new treatment option for adults with a specific type of advanced colon cancer that has spread to other parts of the body (metastatic colorectal cancer). This approval is for the drug combination of Braftovi (encorafenib), cetuximab, and FOLFOX, which can now be used as the first treatment for patients whose cancer has a genetic mutation called BRAFV600E. Laboratoires Pierre Fabre, the company behind Braftovi, announced this important decision after reviewing results from a large clinical trial called the Breakwater study. In this trial, researchers compared the new combination to standard chemotherapy treatments in patients who had not received any prior treatment for their advanced cancer. The new combination showed significant benefits: patients lived longer without their cancer getting worse (progression-free survival) compared to those on chemotherapy alone. On average, the new combination kept cancer from worsening for 12.8 months, while chemotherapy alone did so for 7.1 months. Additionally, more patients responded to the new treatment, with 65.7% showing a reduction in tumor size compared to 37.4% with chemotherapy. Importantly, the new treatment also helped patients live longer overall, with an average survival of 30.3 months versus 15.1 months for chemotherapy, reducing the risk of death by 51%. The most common side effects of the new combination were nausea, low red blood cell counts (anemia), and diarrhea, which are consistent with the known side effects of the individual drugs. Nùria Perez-Cullel, Head of Medical, Patient, and Consumer Affairs at Laboratoires Pierre Fabre, emphasized the importance of this approval for patients with this specific type of colon cancer, where treatment options have historically been limited. The company is committed to making this treatment available to patients in need.